Tumor, Solid Clinical Trial
Official title:
Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR)
The primary objective of this protocol is to evaluate the feasibility of acquiring simultaneous 4D ultrasound and 4D MRI scans. The imaging performance of the US and MRI scans will be characterized. The secondary objective of this study is to determine if several salient features identified in the US scan can be used to predict target motion identified in the MR scan.
The goal of radiotherapy treatment of cancer is to cure or locally control the disease while minimizing complications to healthy tissue. Given the complexity of tumor and normal tissue response to radiation, precise and accurate delivery of absorbed dose distributions, within known tolerances, is necessary to achieve the maximum therapeutic ratio. The complex treatment process of radiotherapy introduces geometrical uncertainties including respiratory induced tumor motion. The goal of this research is to develop and validate a novel image-guidance technique to directly track tumor motion using a 4-dimensional (4D) planar ultrasound (US) transducer during radiation therapy that is coupled to a pre-treatment calibration training image set consisting of a simultaneous 4D ultrasound and 4D magnetic resonance imaging (MRI) acquisition. The image sets will be rapidly matched using advanced image and signal processing algorithms, allowing the display of virtual MR images of the tumor/organ motion in real-time from an ultrasound acquisition. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT05637034 -
68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer
|
N/A | |
Recruiting |
NCT05378425 -
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
|
Phase 1 | |
Not yet recruiting |
NCT04723810 -
TumorGlow Intraoperative Molecular Imaging (IMI)
|
Phase 1/Phase 2 | |
Recruiting |
NCT06116032 -
Immune Profiling for Cancer Immunotherapy Response
|
||
Recruiting |
NCT06090266 -
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Recruiting |
NCT04416165 -
Comparison of FDG and FAPI in Patients With Various Types of Cancer
|
N/A | |
Recruiting |
NCT05620134 -
Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04750772 -
Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer
|
N/A | |
Recruiting |
NCT06022029 -
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
|
Phase 1 | |
Terminated |
NCT01358331 -
A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)
|
Phase 1 | |
Recruiting |
NCT06175221 -
Autologous TLPO Vaccine Basket
|
Phase 2 | |
Recruiting |
NCT05661461 -
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
|
Phase 1 | |
Active, not recruiting |
NCT04196530 -
BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab
|
Phase 1 | |
Not yet recruiting |
NCT03731390 -
GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT03491631 -
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06193902 -
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04528836 -
First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05221320 -
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04367948 -
Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma
|
N/A |